122 related articles for article (PubMed ID: 6928231)
21. Epidermal growth factor receptor levels increase but epidermal growth factor receptor ligand levels decrease in mouse mammary tumors during progression from hormone dependence to hormone independence.
Kienhuis CB; Sluyser M; de Goeij CC; Koenders PG; Benraad TJ
Breast Cancer Res Treat; 1993; 26(3):289-95. PubMed ID: 8251654
[TBL] [Abstract][Full Text] [Related]
22. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats.
Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG
Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162
[TBL] [Abstract][Full Text] [Related]
23. Regression of hormone-dependent mammary tumors in Sprague-Dawley rats as a result of tamoxifen or pharmacologic doses of 17 beta-estradiol: cyclic adenosine 3',5'-monophosphate-mediated events.
Bodwin JS; Hirayama PH; Rego JA; Cho-Chung YS
J Natl Cancer Inst; 1981 Feb; 66(2):321-6. PubMed ID: 6256577
[TBL] [Abstract][Full Text] [Related]
24. [Relation between hormone dependency and the estrogen receptor of mammary carcinoma--comparative study of rat and human mammary tumors].
Iwasa Z; Yamamoto M; Tanaka A; Okuno K; Sagara N; Matsuda T; Fukuhara T; Yasutomi M
Gan No Rinsho; 1985 Dec; 31(15):1865-70. PubMed ID: 3937916
[TBL] [Abstract][Full Text] [Related]
25. Antagonistic action between cyclic AMP and estrogen in phosphorylation of mammary tumor nuclear proteins.
Cho-chung YS; Doud FJ
Cancer Lett; 1978 Oct; 5(4):219-24. PubMed ID: 210929
[TBL] [Abstract][Full Text] [Related]
26. Evolution towards hormone independence of the MXT mouse mammary tumor is associated with a gradual change in its estrogen receptor molecular polymorphism.
Piccart MJ; Trivedi S; Maaroufi Y; Debbaudt A; Veenstra S; Leclercq G
Cancer Biochem Biophys; 1998 Jun; 16(1-2):169-82. PubMed ID: 9923975
[TBL] [Abstract][Full Text] [Related]
27. Steroid-hormone-binding proteins in normal and neoplastic mammary tissues from C3H mice fed diethylstilbestrol.
Lewko WM; Wittliff JL
J Toxicol Environ Health; 1983 Jul; 12(1):127-41. PubMed ID: 6632000
[TBL] [Abstract][Full Text] [Related]
28. Nuclear protein phosphorylation and hormone-dependent mammary tumor regression following dibutyryl cyclic adenosine 3':5'-monophosphate treatment or ovariectomy.
Cho-Chung YS; Redler BH; Lewallen RP
Cancer Res; 1978 Oct; 38(10):3405-9. PubMed ID: 210937
[No Abstract] [Full Text] [Related]
29. Influence of prenatal exposure to diethylstilbestrol on estrogen and progestin binding proteins in uteri and dimethylbenzanthracene- induced mammary tumors of the rat.
Heidemann PH; Wittliff JL; Calhoon RE; Boylan ES
J Toxicol Environ Health; 1981 Oct; 8(4):667-86. PubMed ID: 6802985
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic estrogen receptor in a pregnancy-dependent mouse mammary tumor (TPDMT-4) and related autonomous lines.
Matsuzawa A; Mizuno Y; Yamamoto T; Hori T; Suzuki T
Cancer Res; 1980 Sep; 40(9):3361-8. PubMed ID: 7427949
[TBL] [Abstract][Full Text] [Related]
31. Concurrent changes in growth-related biochemical parameters during regression of hormone-dependent rat mammary tumors.
Foecking MK; Abou-Issa H; Webb TE; Minton JP
J Natl Cancer Inst; 1983 Oct; 71(4):773-8. PubMed ID: 6312151
[TBL] [Abstract][Full Text] [Related]
32. Increased DNA binding of the estrogen receptor in an estrogen-resistant mammary cancer.
Baskevitch PP; Vignon F; Bousquet C; Rochefort H
Cancer Res; 1983 May; 43(5):2290-7. PubMed ID: 6403233
[TBL] [Abstract][Full Text] [Related]
33. Subcellular distribution of cyclic adenosine 3',5'-monophosphate-binding protein and estrogen receptors in control pituitaries and estrogen-induced pituitary tumors.
Piroli G; Weisenberg LS; Grillo C; De Nicola AF
J Natl Cancer Inst; 1990 Apr; 82(7):596-601. PubMed ID: 1690304
[TBL] [Abstract][Full Text] [Related]
34. Hypothesis. Cyclic AMP and its receptor protein in tumor growth regulation in vivo.
Cho-Chung YS
J Cyclic Nucleotide Res; 1980; 6(3):163-77. PubMed ID: 6255017
[TBL] [Abstract][Full Text] [Related]
35. Cyclic AMP receptor triggers nuclear protein phosphorylation in a hormone-dependent mammary tumor cell-free system.
Cho-Chung YS; Archibald D; Clair T
Science; 1979 Sep; 205(4413):1390-2. PubMed ID: 224463
[TBL] [Abstract][Full Text] [Related]
36. Role of estrogen and prolactin in the growth and receptor levels of N-nitrosomethylurea-induced rat mammary tumors.
Manni A; Rainieri J; Arafah BM; Finegan HM; Pearson OH
Cancer Res; 1982 Sep; 42(9):3492-5. PubMed ID: 6286107
[TBL] [Abstract][Full Text] [Related]
37. The biochemical mechanisms of the stimulating action of estradiol on the growth of mammary tumours.
Morozova TM; Mitina RL; Nagibneva IN; Ozhogina ZB; Salganik RI
Exp Clin Endocrinol; 1986 Dec; 88(3):293-302. PubMed ID: 3030784
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor profiles: changes in mouse and rat mammary tumors by treatment with selective estrogen receptor modifiers.
Actis AM; Cocca CM; Gutierrez A; Croci M; Rivera ES; Bergoc RM
Med Princ Pract; 2004; 13(4):220-6. PubMed ID: 15181328
[TBL] [Abstract][Full Text] [Related]
39. Effects of host hormonal status on binding of activated estrogen receptor to nuclei from R3230AC and 7,12-dimethylbenz[a]anthracene-induced mammary tumors.
Klinge CM; Bambara RA; Zain S; Hilf R
Cancer Res; 1989 Mar; 49(5):1165-70. PubMed ID: 2492902
[TBL] [Abstract][Full Text] [Related]
40. Regulatory interrelationships for insulin and estrogen action in mammary tumors.
Hilf R; Hissin PJ; Shafie SM
Cancer Res; 1978 Nov; 38(11 Pt 2):4076-85. PubMed ID: 100214
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
